Access & Legality
    Retatrutide

    How to Verify Your Retatrutide Source

    Before injecting anything into your body, you need to know where it came from and whether it is what it claims to be. Here is a step-by-step verification process for retatrutide sources.

    Published: April 3, 202612 min read

    The gap between retatrutide's extraordinary Phase 2 results (Jastreboff et al., NEJM 2023) and its current unavailability as an FDA-approved drug has created a market filled with sources of varying legitimacy. Some are licensed compounding pharmacies producing quality products. Others are unregulated vendors selling untested chemicals. Telling them apart requires knowing what to look for and what questions to ask.

    Safety First

    Retatrutide is not FDA-approved. Always work with a licensed healthcare provider and use only licensed pharmacy sources. This guide helps you evaluate sources but does not endorse any specific pharmacy.

    Step 1: Verify Pharmacy Licensure

    Every legitimate compounding pharmacy must be licensed by their state board of pharmacy. You can verify this by visiting your state's board of pharmacy website (or the pharmacy's home state) and searching for their license number. The pharmacy should prominently display their license information. If they do not have a verifiable state pharmacy license, stop -- they are not a legitimate pharmacy.

    Step 2: Confirm Sterile Compounding Capability

    Injectable medications must be compounded in USP 797-compliant sterile environments. Ask the pharmacy whether they have a certified clean room, conduct environmental monitoring, and perform sterility testing on finished products. Not all pharmacies that dispense oral medications are equipped for sterile compounding.

    Step 3: Request Certificate of Analysis

    What a CoA Should Include

    Identity Confirmation

    Test confirming the substance is retatrutide (mass spectrometry or specific assay)

    Purity by HPLC

    Should be 98% or higher; lower purity indicates significant impurities

    Potency Assay

    Confirms concentration matches the label claim (within 90-110% of stated amount)

    Sterility Test

    Confirms no bacterial or fungal growth (essential for injectables)

    Endotoxin Test (LAL)

    Confirms bacterial endotoxin levels are below safe limits

    Testing Laboratory

    Third-party lab is preferable to in-house testing for independence

    Step 4: Evaluate Red Flags

    Warning Signs

    • No prescription required for purchase
    • Product labeled "for research use only" or "not for human consumption"
    • No verifiable US pharmacy license
    • Cannot or will not provide a certificate of analysis
    • Prices dramatically below market (often indicates quality shortcuts)
    • Payment by cryptocurrency or wire transfer only
    • No physical US address or contact phone number
    • Claims that retatrutide is FDA-approved (it is not)
    • Aggressive marketing with unsubstantiated claims

    Step 5: Involve Your Healthcare Provider

    A prescribing physician should be involved in any retatrutide access pathway. Telehealth providers who specialize in weight loss medications often have established relationships with vetted compounding pharmacies, providing an additional layer of quality assurance. Your provider can also monitor your treatment with appropriate lab work and clinical follow-up.

    To explore verified weight loss treatment options, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. This guide does not endorse any specific pharmacy or source. Always work with a licensed healthcare provider. Consult your physician before starting any medication.

    Verified Weight Loss Treatment

    Skip the uncertainty. Semaglutide from $99/mo and tirzepatide from $125/mo with medical oversight.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy for more details about sourcing, updates, and reviewer attribution.

    Was this article helpful?

    Keep Reading

    Read our guide on Retatrutide Compounding Quality.

    Read our guide on Can Glp 1 Reduce Cancer Risk.

    Read our guide on Sarcopenia Risk Glp 1.

    When and how to start semaglutide or tirzepatide after pregnancy. Postpartum GLP-1 guide covering breastfeeding safety, timing, and realistic weight loss expectations.